The number of people with chronic conditions is increasing worldwide. In this context, the demand for Ypsomed’s autoinjectors and pens is growing rapidly, as they enable simple and safe self-administration of liquid medication. In conversation with Susanne Köhler, Head of Public Relations, Ulrike Bauer, Chief Business Officer Delivery Systems at Ypsomed, talks about current trends and how the company’s commitment to strong partnerships, scalable business models, and strategic market positioning makes Ypsomed an ideal partner for meeting the growing demand and driving sustainable innovation.
Q: Ypsomed’s annual figures show that the company is on a steep path of success and growth. What factors are driving this growth?
A: Injectables are alongside orals the dominant category of drugs in the development pipelines of pharma and biotech. The benefits for patients and for the healthcare systems of at-home treatment are increasingly recognised. That is why there is a growing demand for innovative, user-friendly, and reliable devices that enable quick market access. Ypsomed is well positioned to serve these needs due to a comprehensive device portfolio and its established platform approach that was introduced more than ten years ago.
We have trustworthy and longstanding relationships with a huge number of both big and small pharma and biotech customers, which provide the basis for two thirds of every new project that we work on. One third of new projects are started with new customers, so our customer base is steadily increasing.
Q: How does Ypsomed contribute to building and strengthening relationships with customers?
A: We prioritise transparency, trust, and continuous collaboration. We build joint governance structures and maintain open communication to ensure our customers’ needs are consistently met throughout all project phases and the full life cycle. Our platform approach allows us to tailor selfinjection devices to specific pharmaceutical requirements in a short time, thereby reliably supporting successful product launches. Additionally, our proactive risk management practices help sustain longterm, mutually beneficial relationships with both existing and new pharmaceutical and biotech customers.
Q: Who does Ypsomed partner with and why?
A: At Ypsomed, we partner with a broad network of global industry leaders across the pharmaceutical supply chain, including equipment suppliers, contract manufacturing organisations (CDMO/CMOs), and primary container manufacturers.
Our partnerships span the entire development process and commercial life of combination products – from ensuring primary container compatibility to collaborating on fill-finish operations, final product assembly, and packaging. Our Industry Collaboration department, staffed with subject matter experts, has a deep understanding of our partners’ capabilities, and confidently recommends the best options when it comes to equipment selection and manufacturing processes, whether customers choose to manage processes in-house or work with trusted service providers. Our partnerships offer turnkey solutions that are easy to access and ready to order. By nurturing these strategic partnerships, pharma customers benefit from best-in-class systems that reduce costs and shorten timelines during the clinical, approval, and commercial phases for each drug product. Through this extensive network of collaborations, Ypsomed effectively supports customers and maintains the quality and safety they expect.
